Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) — Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveals growing use of subcutaneous (SC) PD-1 therapies alongside expectations for an eventual shift toward […]